Hence, BET inhibitors could be considered as a valuable therapeutic approach for ALS and FTD, even though further studies are essential to better identify the effective dosage, as well as the long-term efficacy in the pathology progression. The gene discussed is DNER; the disease is frontotemporal dementia.